Market Overview

UPDATE: Oppenheimer Downgrades ImmunoGen to Perform on Valuation

Related IMGN
4 After-Hours Movers: Earnings, Strategic Reviews & Offerings Shaking Stocks
Jefferies Sees Risks From Lack Of Data Supporting ImmunoGen Drug Trial, Cuts Price Target In Half
ImmunoGen's (IMGN) CEO Mark Enyedy on Q1 2017 Results - Earnings Call Transcript (Seeking Alpha)

Oppenheimer downgraded ImmunoGen (NASDAQ: IMGN) from Outperform to Perform and maintained a $14.00 price target.

Oppenheimer noted, "We are downgrading IMGN to Perform from Outperform and maintaining our $14 price target, as we believe the success of T-DM1 is now fully priced into the stock. We are warming to IMGN901 and will watch the NORTH study as it will likely be the next driver of IMGN that could move us off the sidelines. A NORTH update is expected 2H13. With the launch of T-DM1, as with any drug launch, initial Street expectations may be adjusted. A post-launch pullback in IMGN into low teens may also cause us to revisit our rating."

ImmunoGen closed at $15.04 on Friday.

Latest Ratings for IMGN

Aug 2016JefferiesMaintainsBuy
Aug 2016JP MorganMaintainsNeutral
May 2016RBC CapitalDowngradesOutperformSector Perform

View More Analyst Ratings for IMGN
View the Latest Analyst Ratings

Posted-In: OppenheimerAnalyst Color Downgrades Pre-Market Outlook Analyst Ratings


Related Articles (IMGN)

View Comments and Join the Discussion!